Research Topics
Genomes and GenesSpecies | Fairooz F KabbinavarSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trialsFairooz F Kabbinavar
Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, 2333D PVUB MC 705907, 10945 Le Conte Ave, Los Angeles, CA 90095 7059, USA
J Clin Oncol 27:199-205. 2009....- Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerFairooz Kabbinavar
Division of Hematology Oncology, University of California Los Angeles, School of Medicine, 90095, USA
J Clin Oncol 21:60-5. 2003.... - Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancerFairooz F Kabbinavar
Division of Hematology Oncology, University of California at Los Angeles, California 90095 7059, USA
Oncologist 13:1021-9. 2008.... - Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline riskFairooz Kabbinavar
University of California Los Angeles, Los Angeles, California 90095 7059, USA
Oncology 75:215-23. 2008..This model was applied to data from phase II/III trials of first-line bevacizumab plus 5-FU/LV with/without irinotecan (IFL)... - Angiogenesis and angiogenic inhibitors in renal cell carcinomaRishi Sawhney
Division of Hematology Oncology, David Geffen School of Medicine at UCLA, 10945 LeConte Avenue, Suite 2333D, Box 957059, Los Angeles, CA 90095, USA
Curr Urol Rep 9:26-33. 2008..This article reviews the role of angiogenesis in RCC and summarizes data regarding antiangiogenic therapy in metastatic RCC... - Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?Fairooz F Kabbinavar
Division of Hematology Oncology, Department of Medicine, 10945 Le Conte Ave, University of California Los Angeles 2338 John, PVUB MC, 718707, Los Angeles, CA 90095 7187, USA
Clin Colorectal Cancer 4:S69-73. 2004..The current study indicates that subpopulations of patients with advanced age or poor performance status could be treated successfully with 5-FU/LV in combination with bevacizumab without excessive toxicities... - Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trialFairooz F Kabbinavar
Division of Hematology Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095 7187, USA
J Clin Oncol 23:3697-705. 2005..This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan... - Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapiesArie S Belldegrun
Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
Cancer 113:2457-63. 2008..The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured... - Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomyTobias Klatte
Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, 66 118 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
Cancer Epidemiol Biomarkers Prev 18:894-900. 2009..To identify the molecular signature of localized (N0M0) clear cell renal cell carcinoma (RCC) and assess its ability to predict outcome... - Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free intervalTobias Klatte
Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
J Urol 177:2081-6; discussion 2086-7. 2007..We evaluated the prognosis, risk factors and relevance of the primary-free interval in a large cohort with metachronous bilateral renal cell carcinoma... - Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinomaTobias Klatte
Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Clin Cancer Res 13:7388-93. 2007..Here, we evaluated the significance of HIF-1 alpha in renal cell carcinoma (RCC)... - Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerFairooz F Kabbinavar
University of California Los Angeles, Los Angeles, CA, USA
J Clin Oncol 23:3706-12. 2005..1% v 24.5%; P = .019). CONCLUSION: The addition of bevacizumab to FU/LV provides a statistically significant and clinically relevant benefit to patients with previously untreated metastatic colorectal cancer... - CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosisMichela de Martino
Department of Urology, University of California Los Angeles, Los Angeles, California 90095 1738, USA
J Urol 182:728-34. 2009..The CA9 gene exons and flanking regions were amplified by polymerase chain reaction and sequenced. The monoclonal antibody M75 was used to evaluate CAIX protein expression in the primary tumor by immunohistochemistry... - Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigmBrian Shuch
Department of Urology, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
BJU Int 102:692-6. 2008.... - Smoking negatively impacts renal cell carcinoma overall and cancer-specific survivalNils Kroeger
Institute of Urologic Oncology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095 7207, USA
Cancer 118:1795-802. 2012..The authors of this report retrospectively studied the impact of smoking on clinicopathologic factors, survival outcomes, and p53 expression status in a large cohort of patients with RCC... - Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classificationTobias Klatte
Department of Urology, University of California Los Angeles, Los Angeles, California, USA
J Urol 181:1558-64; discussion 1563-4. 2009..We performed the first prospective study of necrosis in clear cell renal cell carcinoma to our knowledge and tested the traditional presence/absence classification vs an alternative extent based classification... - Pathobiology and prognosis of chromophobe renal cell carcinomaTobias Klatte
Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Urol Oncol 26:604-9. 2008..To analyze pathobiology and prognosis of chromophobe renal cell carcinoma (CRCC)... - Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell featuresTobias Klatte
Department of Urology, University of California Los Angeles, Los Angeles, California, USA
J Urol 185:30-5. 2011..Typically the cells have a chromophilic appearance but areas may show cells with clear cytoplasm, similar to those in clear cell renal cell carcinoma... - Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinomaNils Kroeger
Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA Department of Urology, University Hospital Greifswald, Greifswald, Germany
Eur Urol 61:888-95. 2012..While it is well known that clear cell renal cell carcinoma (ccRCC) that presents with lymphatic spread is associated with an extremely poor prognosis, its molecular and genetic biology is poorly understood... - Brain metastasis from renal cell carcinoma: presentation, recurrence, and survivalBrian Shuch
Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
Cancer 113:1641-8. 2008..The objective of the current study was to assist in the creation of treatment guidelines... - Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinomaTobias Klatte
Department of Urology, David Geffen School of Medicine at UCLA, Center for Health Sciences, Los Angeles, CA 90025 1738, USA
J Clin Oncol 27:746-53. 2009..We prospectively studied the prognostic impact of cytogenetic abnormalities on a larger cohort of patients having up to 108 months of follow-up... - Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinomaTobias Klatte
Department of Urology, University of California at Los Angeles School of Medicine, Los Angeles, California 90095 1738, USA
Clin Cancer Res 15:1162-9. 2009..The goal of this study was to evaluate immunohistochemical and cytogenetic features and their prognostic value in papillary renal cell carcinoma (PRCC) subtypes... - Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapyBrian Shuch
Department of Urology, David Geffen School of Medicine at University of California Los Angles, Los Angeles, California 90095 1738, USA
Cancer 116:616-24. 2010..The patterns of metastases for these tumors were evaluated to determine if sarcomatoid features were retained at metastasis and whether the percentage of sarcomatoid features in the primary tumor influenced spread... - The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinomaTobias Klatte
Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
J Urol 179:61-6. 2008..To evaluate its role in the biology of clear cell renal cell carcinoma we performed a tissue microarray based study... - Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experienceTobias Klatte
Department of Urology, University of California, Los Angeles, Los Angeles, California 90095 1738, USA, and Centre Hospitalier Universitaire Pontchaillou, Rennes, France
J Urol 178:35-40; discussion 40. 2007..We examined the current pT2 tumor classification of renal cell carcinoma and determined whether a tumor size cutoff exists that would improve prognostic accuracy... - Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinomaTobias Klatte
Department of Urology, University of California Los Angeles, Los Angeles, California 90025 1738, USA
J Urol 183:2143-7. 2010..Recent evidence suggests that nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. We tested this hypothesis in an independent large series from a single institution... - Prognostic factors for renal cell carcinoma with tumor thrombus extensionTobias Klatte
Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
J Urol 178:1189-95; discussion 1195. 2007..We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved... - Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomasTobias Klatte
Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90025 1738, USA
J Urol 179:1719-26. 2008..We characterized the clinicopathological features and the prognosis of small solid renal tumors defined as tumors 4 cm or smaller... - Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinomaTobias Klatte
Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
Cancer 118:5777-82. 2012..The aim of this study was to evaluate the prevalence of chromosome 8q gain in clear cell renal cell carcinoma (CCRCC) and to correlate the findings with tumor phenotype and disease-specific survival (DSS)... - Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort studyFairooz F Kabbinavar
Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, 924 Westwood Blvd, Los Angeles, CA 90095 7207, USA
Eur J Cancer 48:1126-32. 2012..We sought to describe the incidence, temporal pattern, outcomes and potential risk factors for GIP in a large, community-based observational cohort study of patients treated with bevacizumab... - Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigationNils Kroeger
UCLA Institute of Urologic Oncology, David Geffen School of Medicine, Los Angeles, CA, USA
J Urol 187:418-23. 2012..Therefore, a large multicenter study examining the experience of 5 international institutions was performed to evaluate the prognostic value of microvascular invasion in the occurrence of metastases and cancer specific survival... - The Chromophobe Tumor Grading System is the Preferred Grading Scheme for Chromophobe Renal Cell CarcinomaDavid S Finley
Institute of Urologic Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
J Urol 186:2168-74. 2011..We compared the 2 scoring systems in a large sporadic chromophobe renal cell carcinoma cohort to determine which grading scheme provides the most predictive assessment of clinical risk... - Functional and oncological outcomes of partial nephrectomy of solitary kidneysJeffrey La Rochelle
Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
J Urol 181:2037-42; discussion 2043. 2009.... - Performance status and cytoreductive nephrectomy: redefining management in patients with poor performanceBrian Shuch
Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
Cancer 113:1324-31. 2008..The objective of the current study was to investigate the outcomes of cytoreductive nephrectomy (CN) for patients who have an impaired performance status (ECOG PS 2/3)... - Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cellsM Jane Arboleda
Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA
Cancer Res 63:196-206. 2003..Taken together, these data indicate that AKT2 mediates PI3-K-dependent effects on adhesion, motility, invasion, and metastasis in vivo... - A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCarolyn D Britten
David Geffen School of Medicine at the University of California, Los Angeles 90095, USA
Cancer Chemother Pharmacol 61:515-24. 2008..This trial was performed to investigate the safety, tolerability, and pharmacokinetics of sunitinib 50 mg daily for 2 weeks followed by a 1-week off period (2/1 schedule)... - Irinotecan treatment for recurrent malignant glioma using an every-3-week regimenTimothy F Cloughesy
UCLA School of Medicine, Henry Singleton Brain Cancer Research Program, Los Angeles, California, USA
Am J Clin Oncol 25:204-8. 2002..The concurrent use of anticonvulsant medications may have played a role in altering pharmacokinetics and thus the maximum tolerated dose in this patient population... - A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)Sara A Hurvitz
David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Clin Breast Cancer 10:307-12. 2010..To assess the activity of docetaxel plus bevacizumab, a multicenter phase II trial was conducted... - Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimenTimothy F Cloughesy
Henry Singleton Brain Cancer Research Program, UCLA School of Medicine, Los Angeles, California 90095, USA
Cancer 97:2381-6. 2003..A higher level of efficacy for CPT-11 may be observed if an MTD can efficiently be established for each patient... - Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experienceTobias Klatte
Department of Urology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
BJU Int 100:21-5. 2007..To present a multicentre experience and the largest cohort to date of nonmetastatic (N0M0) synchronous bilateral renal cell carcinoma (RCC), as because it is rare the single-institutional experience is limited... - Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinomaJeffrey La Rochelle
Department of Urology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California 90025, USA
Cancer 116:4696-702. 2010.... - Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinomaDavid J Vaughn
Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer 100:746-50. 2004..The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen-independent prostate carcinoma (AIPC)... - Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerDavid H Johnson
Division of Hematology and Oncology, Vanderbilt University Medical School, 777 Preston Research Bldg, Nashville, TN, USA
J Clin Oncol 22:2184-91. 2004..To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer... - Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerRonald M Bukowski
Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Clin Oncol 25:4536-41. 2007.... - Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urotheliumChristopher J Sweeney
Hoosier Oncology Group, Indianapolis, IN, USA
J Clin Oncol 24:3451-7. 2006..CONCLUSION: Single-agent pemetrexed is safe and active as second-line treatment of patients with advanced TCC of the urothelium. Additional evaluation in the first- or second-line setting in TCC of the urothelium is warranted...